Hospira received a positive opinion from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP), recommending European Commission approval of Inflectra (infliximab) for rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis.
Inflectra (infliximab) is a biosimilar medicine to the reference medicinal product, Remicade (infliximab), and is the first monoclonal antibody therapy to reach a positive opinion following review via the EMA biosimilars regulatory pathway. A biosimilar developed in-line with EU requirements can be considered a therapeutic alternative to an existing biologic, with comparable quality, efficacy and safety to the reference product.
Biologic medicines have led to vast improvements in the treatment of conditions such as rheumatoid arthritis and inflammatory bowel disease, but they also represent one of the biggest medical expenditures in many countries.
Inflectra specifically targets tumor necrosis factor (TNF) alpha, a protein in the body that contributes to the painful inflammation seen in rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis. The drug's safety, efficacy and tolerability have been established through a comprehensive clinical trial program. In a phase III randomized, double-blind study, Inflectra met its primary endpoint of therapeutic equivalence to the reference product. In the study, 73.4% of patients receiving Inflectra achieved a greater than 20% improvement in RA symptoms after 30 weeks of treatment (using the ACR20 scoring system), compared with 69.7% treated with reference infliximab. The safety and tolerability of Inflectra was also demonstrated to be comparable to Remicade, supporting its approval.
In 2009, Hospira entered into an agreement with South Korean-based biopharmaceutical company, Celltrion, which is developing eight monoclonal antibody biosimilars. Under the terms of the agreement, Hospira obtained the rights to Inflectra in Europe, the United States, Canada, Australia and New Zealand.
The European Commission reviews the recommendations of the CHMP. The final decision on approval, usually granted within three months of CHMP opinion, will be applicable to all European Union (EU) and European Economic Area (EEA) countries.
Hospira is the only U.S.-based company with biosimilars on the European market, including Retacrit which was launched in Europe in early 2008 and Nivestim, which entered the European market in 2010 and Australian market in 2011.
"In a time when there is mounting pressure on healthcare budgets worldwide, Inflectra provides an opportunity to increase patient access to more affordable biologic therapy while maintaining high quality standards," said Richard Davies, Senior Vice President and Chief Commercial Officer, Hospira.
 Weise M. et al. Blood. 2012; 120: 5111-5117
 Bendtzen, K. Immunotherapy. 2012; 4(11): 1167-1179.
 Hospira Inc, 2013, Data on file.
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- Sam Ting On AMS Results: Dark Matter Might Be One Seminar Away
- Vitriolic Abuse Of Anita Sarkeesian: Why The Games Industry Needs Her
- Why Natural Gas, Including Fracking, Is Better For The Environment Than Wind And Solar
- BICEP2's vision wasn't that strong, Planck says their window was too dusty.
- Mysterious 1808 Eruption - The Real Cause Of The Coldest Decade Of The Last 500 Years
- Graphene Sensor Tracks Down Cancer Biomarkers
- Nature Communications Switching To Exclusive Open Access
- "It's amazing to see the PR machine that Ting has put together at work. Not only do we have to wait..."
- ":) Actually amphetamine salts were not sustainable as an ADHD solution for me. They actually did..."
- "Hi Hontas. This caught my eye: That said, it may be that there simply is no strong signal of inflation..."
- "1.) Fundamentally one can never prove any theory. That's what makes a theory different from..."
- "I thank you for your comment, which I think is very important. Especially the question aboutPerhaps..."
- Note to young men: Fat doesn't pay
- Immune system is key ally in cyberwar against cancer
- Medical students who attended community college likelier to serve poor communities
- Study helps assess impact of temperature on belowground soil decomposition
- Facial masculinity not always a telling factor in mate selection